Table 3. Progression-free and overall survival evaluated according to the hypertension toxicity (grade).
| Grade | No. patients | No. events | Median PFS (months) (95% CI) | p | HR (95% CI) | p |
|---|---|---|---|---|---|---|
| 0 | 26 | 24 | 2.5 (1.8-2.8) | 1.00 | ||
| 1 | 10 | 10 | 2.1 (0.9-2.6) | 0.88 (0.41-1.87) | ||
| 2 | 10 | 9 | 5.2 (1.2-10.8) | 0.30 (0.13-0.71) | ||
| 3 | 15 | 12 | 8.5 (3.2-15.3) | <0.0001 | 0.16 (0.07-0.37) | <0.0001 |
| Grade | No. patients | No. events | Median OS (months) (95% CI) | p | HR (95% CI) | p |
|---|---|---|---|---|---|---|
| 0 | 26 | 21 | 5.8 (3.1-10.4) | 1.00 | ||
| 1 | 10 | 10 | 3.6 (1.1-8.7) | 0.96 (0.45-2.08) | ||
| 2 | 10 | 9 | 15.6 (2.0-23.0) | 0.45 (0.20-1.01) | ||
| 3 | 15 | 11 | 13.2 (5.7-34.2) | 0.011 | 0.32 (0.14-0.71) | 0.016 |
HZ, hazard ratio